Peptide Lab HQ Research Guide
Vesugen
A research-focused compound profile covering Vesugen identity, KED tripeptide research, vascular peptide bioregulator models, endothelial-cell signaling, cellular aging research context, concentration reference, reconstitution reference, and safety considerations.
Compound Data
Compound Profile
| Compound Name | Vesugen |
|---|---|
| Common Research Name | KED tripeptide |
| Common Synonyms | Lys-Glu-Asp, H-Lys-Glu-Asp-OH, lysyl-glutamyl-aspartic acid, KED peptide, T-38 peptide, Vezugen spelling variant |
| Compound Type | Synthetic ultrashort tripeptide / vascular peptide bioregulator research compound |
| CAS Number | Commonly listed as 204271-66-9; verify against supplier COA |
| PubChem CID | 87571363 |
| Amino Acid Length | 3 amino acids |
| Amino Acid Sequence | Lys-Glu-Asp |
| Short Sequence | KED |
| Molecular Formula | C₁₅H₂₆N₄O₈; verify against supplier COA |
| Molecular Weight | Approximately 390.39 g/mol; verify against supplier COA |
| Research Category | Peptide bioregulator, vascular endothelial research, endothelial-cell proliferation, Ki-67 expression context, vascular aging models, microcirculation research, and cellular aging-marker research |
| Research Context | Commonly discussed in ultrashort peptide bioregulator research involving vascular endothelial cells, age-associated proliferation markers, vascular tissue response, epigenetic regulation, and endothelial function models. |
| Appearance | White to off-white lyophilized powder, depending on supplier documentation |
| Use | For laboratory research use only. |
Research Applications
Key Research Applications
Vesugen is commonly discussed in controlled research models involving KED tripeptide activity, vascular peptide bioregulation, endothelial-cell function, Ki-67 expression context, cellular proliferation markers, vascular aging models, microcirculation research, and cellular stress-response observations.
Peptide Bioregulator Research
Vesugen is commonly positioned within ultrashort peptide bioregulator research, where short amino acid sequences are studied for tissue-specific signaling and gene-expression related effects.
Vascular Endothelial Models
Vesugen is commonly discussed in vascular endothelial research involving endothelial-cell function, vessel-wall response, and age-associated vascular model observations.
Ki-67 / Proliferation Context
KED peptide research has been discussed in relation to Ki-67 expression, cellular proliferation markers, and tissue-specific aging models.
Microcirculation Research
Vesugen is commonly framed around vascular tone, microcirculatory response, capillary resistance, endothelial integrity, and tissue perfusion research contexts.
Cellular Aging Models
Short peptide bioregulator research commonly evaluates aging-associated changes in gene expression, chromatin state, cell proliferation, and tissue-specific cellular response.
Neurovascular / Stem-Cell Context
KED peptide has also been discussed in broader short-peptide research involving stem-cell differentiation, neuroprotective models, and neuronal differentiation context.
Research Scope
These applications are provided for educational and research-reference purposes only. Vesugen research is limited compared with major peptide categories, and outcomes may vary based on peptide identity, purity, study model, concentration, exposure duration, tissue model, and laboratory conditions.
Reference Only
Reconstitution / Research Dosing Reference
Quick Reference Summary
| Reference Vial | 20 mg Vesugen |
|---|---|
| Primary Solution Volume | 1.0 mL bacteriostatic water |
| Primary Concentration | 20 mg/mL |
| Measurement Reference | On a U-100 syringe, 1 unit = 0.01 mL. |
| Amount per U-100 Unit | At 20 mg/mL, 1 unit equals 0.2 mg / 200 mcg Vesugen. |
| Storage Reference | Refrigerate at 2–8°C / 35.6–46.4°F after reconstitution, protected from direct light. |
Reconstitution Steps
- Draw 1.0 mL bacteriostatic water using a sterile syringe for the main concentration reference shown below.
- Slowly add the BAC water down the side of the vial wall.
- Gently roll or swirl the vial until the material is completely dissolved. The solution should appear clear to slightly hazy depending on concentration and supplier format. Do not shake!
- Because this is a concentrated 20 mg/mL preparation, verify complete dissolution before recording final preparation details.
- Label with compound name, vial amount, concentration, solvent volume, preparation date, storage conditions, and handling notes.
- Store refrigerated at 2–8°C / 35.6–46.4°F, protected from direct light.
Published Research Context
| Reference Type | Reported Amount / Context | Research Notes |
|---|---|---|
| Compound Identity Reference | Vesugen, commonly referenced as KED / Lys-Glu-Asp | Vesugen is commonly discussed as a synthetic tripeptide bioregulator associated with vascular, endothelial, tissue-specific, and cellular-aging research contexts. |
| Peptide Bioregulator Research | Model-dependent concentration and endpoint tracking | Commonly discussed in short-peptide bioregulator, DNA / chromatin interaction, gene-expression, cellular-response, and tissue-specific regulatory research contexts. |
| Vascular / Endothelial Research Context | Experimental and model-dependent context | Vesugen-related research discussions commonly include vascular-wall models, endothelial-cell response, vascular tissue markers, proliferation markers, and tissue-specific cell-culture observations. |
| Cellular-Aging Research Context | Ki-67, proliferation-associated, and age-related marker context | Published peptide bioregulator discussions include tissue-specific cellular-aging markers, proliferative-activity markers, and age-associated cell-culture observations depending on the model. |
| Gene-Expression Research Context | Short peptide / DNA interaction context | Short peptide bioregulator literature commonly discusses DNA interaction, regulatory sequence context, chromatin structure, and changes in gene-expression marker patterns depending on the model. |
| Public Protocol-Style Reference | Milligram-range reference examples | Public protocol-style references commonly describe Vesugen in milligram-range examples. These are not clinical dosing standards. |
| Clinical / Research-Chemical Status | No universal research-chemical protocol established | Published study references, public protocol-style references, clinical-use references, or wellness protocols should not be treated as dosing instructions for research-chemical vial formats. |
Concentration Reference
| Vial Amount | Solution Volume | Final Concentration |
|---|---|---|
| 20 mg | 1.0 mL | 20 mg/mL |
Research Dosing Amount / Volume Reference
| Reference Amount | Volume at 20 mg/mL | U-100 Unit Reference | Approx. References per 20 mg Vial |
|---|---|---|---|
| 0.5 mg / 500 mcg | 0.025 mL | 2.5 units | 40 |
| 1 mg / 1000 mcg | 0.05 mL | 5 units | 20 |
| 2 mg / 2000 mcg | 0.10 mL | 10 units | 10 |
| 5 mg / 5000 mcg | 0.25 mL | 25 units | 4 |
| 10 mg / 10000 mcg | 0.50 mL | 50 units | 2 |
| 20 mg / 20000 mcg | 1.00 mL | 100 units | 1 |
Research Frequency / Amount Reference
| Research Window | Frequency | Reference Amount | Units / Volume Reference |
|---|---|---|---|
| Lower Conversion Reference | Public protocol-style reference, not a clinical dosing standard | 0.5 mg reference amount | 2.5 units / 0.025 mL |
| Standard Conversion Reference | Public protocol-style reference, not a clinical dosing standard | 1 mg reference amount | 5 units / 0.05 mL |
| Mid-Range Conversion Example | Calculation reference only | 2 mg reference amount | 10 units / 0.10 mL |
| Upper Conversion Example | Calculation reference only | 5 mg reference amount | 25 units / 0.25 mL |
| High Conversion Example | Calculation reference only | 10 mg reference amount | 50 units / 0.50 mL |
| Full-Vial Preparation Reference | Preparation-level calculation reference | 20 mg reference amount | 100 units / 1.00 mL |
Common Research Windows
| Reference Window | Common Length | Research Notes |
|---|---|---|
| Cell-Culture / Vascular Marker Window | 24–72 hours | May be used for vascular-cell response, endothelial-marker, proliferation-marker, gene-expression, tissue-specific marker, or peptide-response documentation depending on the model. |
| Acute Cellular Observation Window | Single session to several days | Used for early response tracking, vascular-marker comparison, endothelial-cell observation, or short-term pathway documentation depending on the research design. |
| Short Research Window | 1–2 weeks | May be used for short-duration controlled observation involving vascular-wall models, endothelial-cell response, cellular-aging markers, or gene-expression endpoints. |
| Standard Protocol-Style Window | 2–4 weeks | Commonly used in public protocol-style references for structured observation and comparison across baseline and follow-up periods. |
| Extended Observation Window | 4–8 weeks | Used when longer documentation is needed for vascular-marker trends, tissue-specific response markers, cellular-aging context, or follow-up marker tracking. |
| Follow-Up / Washout | 1–4 weeks | Used to document post-study observations, marker return, delayed response patterns, or follow-up data depending on the research model. |
Research Note: These tables are provided for educational, research-planning, concentration, frequency-reference, and volume-reference purposes only. Vesugen, commonly referenced as KED / Lys-Glu-Asp, is discussed in peptide bioregulator, vascular-wall, endothelial-cell, proliferation-marker, Ki-67, gene-expression, DNA / chromatin interaction, tissue-specific response, and cellular-aging research contexts. This reference uses a 20 mg vial reconstituted with 1.0 mL bacteriostatic water, creating a 20 mg/mL concentration. Higher-concentration preparations may require supplier-specific handling, solvent-volume, or solubility notes; verify against the COA, batch record, or formula record when available. Published study references and public protocol-style frequency references are not universal research-chemical dosing standards and should not be treated as dosing instructions for research-chemical vial formats. This information is not medical advice, dosing instruction, injectable-use guidance, or a recommendation for human or animal use.
Research Notes
Research Findings & Safety Notes
Research Findings
Vesugen is commonly discussed in research involving KED tripeptide signaling, vascular peptide bioregulation, endothelial-cell response, Ki-67 expression context, cellular proliferation markers, vascular aging models, microcirculation, and short-peptide gene-expression research.
Study Limitations
Vesugen research is limited compared with major peptide categories and includes endothelial-cell, vascular aging, cellular proliferation, neurogenesis, and peptide bioregulator references. Findings should be interpreted according to peptide identity, purity, study model, concentration, exposure duration, and endpoint selection.
Safety Considerations
Research discussion should account for peptide identity verification, KED sequence confirmation, vascular-response context, sterility documentation, endotoxin risk, supplier qualification, batch records, storage conditions, route-specific uncertainty, and qualified laboratory handling procedures.
Use Restriction
Not for human or animal consumption. Not intended to diagnose, treat, cure, or prevent any disease when discussed as a research-use material.
Related Supplies
Research Supplies
For research supplies, visit our affiliate partner and use code PLHQ10 to save 10% on your order.
Bacteriostatic Water
Commonly referenced in laboratory preparation workflows.
Research Syringes
Supply category for controlled laboratory research preparation.
Prep Supplies
Supporting supplies for clean handling, preparation, and documentation.
Lab Handling
Handling & Storage
Storage
Store materials according to product-specific requirements. Protect from excessive heat, moisture, and direct light.
After Reconstitution
Keep refrigerated after reconstitution unless otherwise specified by the product documentation.
Handling
Use appropriate laboratory PPE, clean handling practices, and qualified research procedures.
Documentation
Maintain batch details, COA records, preparation notes, and internal research documentation.